L’agencia per a la Competitivitat de l’Empresa, ACCIÓ, en data 1 de març de 2018 ha atorgat a Iproteos (Accure Therapeutics) la concessió d’una subvenció per les seves aportacions a les teràpies pel Parkinson
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics
Conferencia online: “La esclerosis múltiple en los próximos 15 años”
Webinars on Neuroprotection for Brain Diseases Program
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
Accure Therapeutics publishes pivotal preclinical efficacy study in epilepsy
Accure Therapeutics appoints Dr. Rossella Medori as chief medical officer
Accure Therapeutics strengthens scientific advisory board by appointing top-class scientists
Accure Therapeutics launches with €7.6M Series A round
